Showing results (11-20 of 151) with videos related to
Sort By:
Pageof 16
Annual Review of Pharmacology and Toxicology|July 28, 2023
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging TherapeuticsErfan Tasdighi, Rishav Adhikari, Omar Almaadawy, et al.Journal of Cardiology Cases|December 15, 2015
Idiopathic 'True' Left Ventricular AneurysmThorsten M Leucker, Vineet Agrawal, Hussein Rahim, et al.European Heart Journal Open|September 2, 2024
Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate riskTarek Harb, Efthymios Ziogos, Roger S Blumenthal, et al.Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|October 11, 2020
The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectivesMichael A Vavuranakis, Steven R Jones, Rhanderson Cardoso, et al.European Journal of Clinical Investigation|June 26, 2024
Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition-Part one: Pleiotropic pro-atherosclerotic effects of PCSK9Alexander M Cao Zhang, Efthymios Ziogos, Tarek Harb, et al.Journal of Clinical Lipidology|January 16, 2026
Tailoring strategies for dyslipidemia management and atherosclerotic cardiovascular disease prevention in muscular dystrophy patientsJelani K Grant, Pooja Selvam, Margaret Koester, et al.European Journal of Clinical Investigation|June 26, 2024
Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition-Part two: Current and emerging concepts in the clinical use of PCSK9 inhibitionAlexander M Cao Zhang, Efthymios Ziogos, Tarek Harb, et al.Trends in Cardiovascular Medicine|April 19, 2021
Coronary heart disease risk: Low-density lipoprotein and beyondGabriel E Shaya, Thorsten M Leucker, Steven R Jones, et al.Atherosclerosis|August 8, 2025
Oxidized phospholipid dynamics in the early post-infarction period: Effects of PCSK9 inhibition with evolocumabMark Atallah, Tarek Harb, Nadim Nasrallah, et al.Journal of Cardiovascular Pharmacology|September 13, 2024
Peroxisome Proliferator-Activated Receptor Gamma Regulates Interleukin-6-Induced Lipoprotein (a) Gene Expression in Human HepG2 CellsTarek Harb, Efthymios Ziogos, Núria Amat-Alarcon, et al.Pageof 16